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Aims Obesity is a risk factor for diabetes and cardiovascular diseases,with the incidenceof these disorders becoming epidemic.
Pathogenic responses toobesity havebeen ascribed to adipose tissue (AT) dysfunction that promotes bioactivemediator
secretion from visceral AT and the initiation of pro-inflammatory events that induce oxidative stress and tissue
dysfunction. Current understanding supports that suppressing pro-inflammatory and oxidative events promotes
improved metabolic and cardiovascular function. In this regard, electrophilic nitro-fatty acids display pleiotropic
anti-inflammatory signalling actions.
Methods
and results
It was hypothesized that high-fat diet (HFD)-induced inflammatory and metabolic responses, manifested by loss of
glucose tolerance and vascular dysfunction, would be attenuated by systemic administration of nitrooctadecenoic acid
(OA-NO2). Male C57BL/6j mice subjected to a HFD for 20 weeks displayed increased adiposity, fasting glucose, and
insulin levels, which led to glucose intolerance and pulmonary hypertension, characterized by increased right ventricular
(RV) end-systolic pressure (RVESP) and pulmonary vascular resistance (PVR). This was associated with increased lung
xanthine oxidoreductase (XO) activity, macrophage infiltration, and enhanced expression of pro-inflammatory cyto-
kines. Left ventricular (LV) end-diastolic pressure remained unaltered, indicating that the HFD produces pulmonary
vascular remodelling, rather than LV dysfunction and pulmonary venous hypertension. Administration of OA-NO2 for
the final 6.5 weeks of HFD improved glucose tolerance and significantly attenuated HFD-induced RVESP, PVR, RV
hypertrophy, lung XO activity, oxidative stress, and pro-inflammatory pulmonary cytokine levels.
Conclusions These observations support that the pleiotropic signalling actions of electrophilic fatty acids represent a therapeutic
strategy for limiting the complex pathogenic responses instigated by obesity.
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1. Introduction
Obesity affects .1.5 billion people worldwide and is a risk factor for
insulin resistance, Type 2 diabetes mellitus (T2DM), and cardiovascular
diseases (CVDs). Obesity, defined by excess adipose tissue (AT) mass
with accumulation of fat into peripheral organs, is now recognized as
a chronic, low-grade inflammatory disease. Obesity-induced pro-
inflammatory signalling cascades promoteATdysfunction and adipokine
dysregulation which, in turn, lends resistance to salutary signalling
molecules, such as insulin and leptin. Therefore, weight loss would be
predicted to have beneficial effects on insulin resistance and complica-
tions associated T2DM, such as CVDs.
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Obesity-induced adipokine dysfunction promotes systemic vasculo-
pathies including atherosclerosis andhypertension, aswell as pulmonary
diseases including asthma, chronic obstructive pulmonary disease, and
pulmonary hypertension (PH).1–3Notably, PHaffects both the systemic
and pulmonary vasculature and is characterized by vasoconstriction,
vascular proliferation, and remodelling of small pulmonary arteries.
This increases pulmonary vascular resistance (PVR), pulmonary arterial
pressure (PAP), and right ventricular (RV) end-systolic pressure
(RVESP), causing pulmonary arterial obstruction.4 The right ventricle
compensates to preserve cardiac output (CO) by undergoing hyper-
trophy and eventual failure, promoting an increased incidence of mor-
bidity and mortality that is resistant to current therapies.
Pathogenic events underlying PH include endothelial dysfunction,
impairednitric oxide (NO) signalling, and abnormal vesselwall prolifera-
tive responses.5 Chronic inflammation contributes to the pathogenesis
of both obesity-induced metabolic dysfunction and PH.6 AT secretes
cytokines, chemokines, and hormones, collectively referred to as adipo-
kines, which regulate metabolic homeostasis in healthy subjects. The
excess AT, in particular visceral fat, in obese individuals is linked with
decreased adiponectin and increased tumour necrosis factor a
(TNF-a), interleukin (IL-6), and leptin levels. This dysregulated adipo-
kine expression, in turn, induces chronic inflammation and oxidative
stress,7 leading to pathogenic vascular and pulmonary responses. For
example, elevated IL-6, TNF-a, and monocyte chemoattractant
protein-1 (MCP-1) levels contribute to the pathogenesis of pulmonary
arterial hypertension (PAH).8 Plasma IL-6 levels arepredictive for the se-
verity of PH and mortality.9 Consistent with this, mice overexpressing
IL-6 in the lung display pulmonary vascular remodelling, elevated
RVESP, and RV hypertrophy.10
Critical to bothobesity-induced inflammation and PH is the enhanced
generationof oxidizing inflammatory species that reactwithNO, limit its
salutary signalling actions, promote the generation of the secondary
oxidant peroxynitrite, and instigate additional pro-inflammatory signal-
ling reactions.11 A key source of reactive species in the intracellular and
intravascular compartment is xanthine oxidoreductase (XO), which is
elevated in patients with idiopathic PAH.12 Notably, XO inhibition by
allopurinol only modestly limits indices of PAH in rodent models.13,14
Other anti-inflammatory strategies for PH, including the administration
of IL-1 receptor antagonists, anti-MCP-1 gene therapy, and glucocorti-
coids, show only a modest therapeutic benefit. This affirms a significant
unmet need for PH-targeted therapeutic agents.8
A commonproblemwithmostmodalities for treating PH is a focus on
a singlemolecular target that is a componentof amorecomplex seriesof
cascading reactions, motivating a therapeutic strategy that better
addresses the multifaceted aetiology of PH. Electrophilic unsaturated
fatty acids, containing oxo or nitroalkene substituents, display a broad
range of adaptive signalling actions that are a consequence of an ability
to modify protein structure and function. In particular, nitro-fatty acids
(NO2-FAs) are endogenously detectable products of unsaturated fatty
acid reaction with NO and nitrite (NO2
2)-derived nitrogen dioxide
radical (·NO2) that are produced during metabolic stress and inflamma-
tion.15 The nitroalkene moiety undergoes reversible Michael addition
with nucleophiles such as cysteine and histidine, promoting the post-
translational modification of proteins critical to the regulation of inflam-
matory responses.16 Current proteomic, genomic, and model system
studies support that lipid electrophile generation links tissue metabolic
and inflammatory status with adaptive gene expression.16,17 The poten-
tial therapeutic utilityof these species in limitingpathogenic responses to
obesity, such as loss of insulin sensitivity and PH, is encouraged by the
impact of NO2-FAs on inhibiting vascular cell superoxide (O2
·2) and
hydrogen peroxide (H2O2) production, limiting smooth muscle (SM)
cell proliferation and improvement of endothelial function.16–18
Mechanisms accounting for these actions include inhibition of nuclear
factor kappa B (NFkB)-regulated cytokine and adhesion molecule ex-
pression, the up-regulation of anti-inflammatory transcription factor
function and potent non-competitive XO inhibition.15,16,18
Here, we report that the administration of OA-NO2 to a murine
model of high-fat diet (HFD; 60% kcal from fat)-induced obesity
improves both AT function and glucose tolerance and inhibits
pro-inflammatory visceral fat and pulmonary cytokine expression, pul-
monary arterial remodelling, lungmacrophage infiltration, and oxidative
stress. These actions, in turn, prevented increases inRVESP, PVR, andRV
hypertrophy, all hallmarks of PH.
2. Methods
2.1 Animals and experimental design
All animal studies were conducted under the approval of the University
of Pittsburgh Institutional Animal Care and Use Committee (protocol
#1010241A).MaleC57Bl/6jmicewere purchased from Jackson Labora-
tory (Bar Harbor, ME, USA). The HFD was purchased from Research
Diets Inc. (New Brunswick, NJ, USA). Obesity was induced by the
HFD (D12492, with 60% of the adjusted calories derived from a fat)
for 20 weeks beginning at age 6–8 weeks. Age-matched controls were
maintainedon a normal rodent chow(NC)diet (15%of the adjusted cal-
ories derived from fat, Pro LabRHM3000 rodent diet; PMI Feeds, Inc.; St
Louis, MO, USA). Mice were fed ad libitum for 20 weeks and given free
access to water. Food intake and mouse weight were monitored twice
per week. At week 13.5 of the HFD study, mice were anaesthetized
with isoflurane beforeAlzet osmotic pumps (Cupertino,CA,USA) con-
taining vehicle (polyethylene glycol/ethanol), native oleic acid (OA), or
the fatty acid nitroalkene derivative 9- and 10-nitro-octadec-9-enoic
acid (OA-NO2) were implanted subcutaneously in the back region, as
previously described.19 The osmotic mini-pump delivered a concentra-
tion of 8 mg/kg/day for OA andOA-NO2. Febuxostat (RS026; BioTang,
Waltham, MA, USA) was delivered in the drinking water (0.05 mg/mL,
5 mg/kg/day).20 The stability of febuxostat in the drinking water was
maintained at or above 94% (capacity to inhibit XO) up to 9 days. To
ensure integrity, febuxostat-containing water was replaced every
5 days. Water consumption was closely monitored to ensure no differ-
ences between treatment groups. Therewere three separate cohorts of
mice that were randomly divided up afterWeek 13.5 into the following:
(i) obesity/metabolic syndrome measurements (Figures 1–3), haemo-
dynamic measurements (Figures 4–5), and haemodynamic measure-
ments with HFD mice treated with febuxostat. For Cohort 1
(Figures 1–3), the number of mice were age-matched on NC (n ¼ 7)
and all other treatment groups on HFD were n ¼ 6. For Cohort 2
(Figures 4–5) illustrating the pressure–volume (PV) loop haemodynam-
icmeasurements, therewere age-matched onNC (n ¼ 6), HFD treated
with OA-NO2 (n ¼ 6), HFD alone (n ¼ 6), HFD with vehicle (n ¼ 4),
and HFD with OA (n ¼ 4). For Cohort 3 (Figure 6), there were two
groups consisting of HFD and HFD with febuxostat (n ¼ 8 for both).
At Week 18.5, the glucose tolerance test (GTT) and dual-energy
X-ray absorptiometry (DEXA) were performed on all cohorts with
the mice being divided up so they would not get both measurements
during the same week. We wanted to minimize the stress on the mice
from the glucose load and the anaesthesia during the body composition
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analysis. At the end of the 20-week study, mice were euthanized with
sodium pentobarbital (100 mg/kg IP) to deeply anaesthetize and con-
firmed by exsanguination. For the haemodynamic studies, mice were
sacrificed by a direct injection of the open chest with pentobarbital
(50 mg/g) followed by iv bolus injection of 500 mL of KCl solution
(pharmaceutical grade).
2.2 In vivo studies
Mice were fasted for 5 h for blood glucose, insulin, and GTT. Blood
glucose levels were measured using a hand-held glucometer (Accu-
Chek Aviva, Roche Diagnostics, Indianapolis, IN, USA). For GTT, mice
were fasted and then injected intraperitoneally with filter-sterilized
1.5 g/kg glucose in 0.9% NaCl. For body composition, bone mineral
density, fat mass, lean mass, and percentage of fat were determined
using DEXA (GE Medical Systems, Madison, WI, USA).
2.3 Plasma collection and measurements
Mice were fasted for 5 h before all blood collections. Plasma was sepa-
rated by centrifugation, aliquoted, and stored at 2808C. Insulin and
leptin measurements were performed using radioimmunoassays (Van-
derbilt University Hormone Assay & Analytical Services Core).
Pro-inflammatory cytokines [macrophage inflammatory protein-1a
(MIP-1a), IL-6, and TNF-a] and adiponectin were determined using
Luminex xMAP technology (EMD Millipore, Billerica, MA, USA). The
multiplex cytokine plate and singleplex adiponectin plate were mea-
sured as per the manufacturer’s instructions.
2.4 Haemodynamic measurements
In vivo PV loop measurements of RV and left ventricular (LV) function
were performed by an PV catheter in anaesthetized mice. Isoflurane
was used throughout the procedure (5% for induction, 2% during
surgery, and 1%while performing PV loopmeasurements). Following in-
duction of anaesthesia, a four-electrode PV catheter (1.0 Fr, Scisense,
Inc., London, ON, USA) attached to the data acquisition system
(EMKA Instruments; Falls Church, VA, USA) was inserted sequentially
into the apex of the RV and LV. RV and LV function were assessed
under steady-state conditions and with transient inferior vena caval oc-
clusion as previously described.21,22 Following ventricular assessment of
PV loop relationships, a 20 mHzDoppler probewasplacedover thepul-
monary artery and then over the aortic arch to assess CO and Doppler
waveforms (DSPW; Indus Instruments, Houston, TX, USA). These
assessments will be referred as PH (pre-clinical model), but the low
LV pressures suggest that this is a model of PAH.
2.5 Right ventricle hypertrophy
After the heart was excised, RV hypertrophy measurement was deter-
mined by Fulton’s Index. The RV wall was dissected, and the remaining
LV wall and ventricular septumwere weighed. Fulton’s Index was calcu-
lated as the ratio of RV weight/(LV + septum weight).
2.6 Immunohistochemistry and image
analysis
Lungs were perfused with phosphate-buffered saline (PBS) through the
RV. Lungswere then inflatedandfixed as previously described.23 Tissues
Figure1 HFD inducesweight gain and adiposity. (A) Mice subjected toHFDorNCwereweighedweekly. (B and C) Fat tissuewas determined byDEXA
and abdominal fat pads were weighed at sacrifice. There was no statistical significance between HFD and HFDmice treated with OA-NO2 for the last 6.5
weeks. Data represent mean+ SEM;wP, 0.001 to NC; %P, 0.05 to NC; no significance between HFD and HFD +OA-NO2 (n ≥ 6 per group).
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were sectioned (7 mm), and immunohistochemical analysis was per-
formed using anti-SM actin (SMA; C6198; Sigma, St Louis, MO, USA),
anti-F4/80 (552958; BD Biosciences, San Jose, CA, USA), anti-CD31
(ab32457-100; Abcam, Cambridge, MA, USA), and/or anti-XO
(200-4683; Rockland Immunochemicals, Gilbertsville, PA, USA). Con-
focal images were obtained using an Olympus Fluoview 1000
(Olympus, Bethlehem, PA, USA). For imaging analysis, vascular remod-
elling was assessed by measuring the thickness of the SM layer using the
NIS Elements software (Nikon Instruments, Inc., Melville, NY, USA).
Thickness measurements were made by first generating a binary mask
of the SMA staining and defining the centroid region of each vessel.
Lines (arm) were then drawn from this central point to the external
margin of the SMA mask and the length of each arm determined by
object counting. The thickness measurement for each individual vessel
was comprised of an average of 15 length measurements per vessel.
Two to four images (with 1–3 vessels per image) were analysed from
each animal. XO abundance (anti-XO staining) andmacrophage infiltra-
tion (anti-F4/80 staining)werequantifiedusing theMetaMorph software
(Molecular Devices, Sunnyvale, CA, USA) and expressed relative to
nuclear counts [4′,6-diamidino-2-phenylindole (DAPI) staining].
2.7 XO activity and protein expression
Enzymatic activity was determined as previously described.18 XO ex-
pression was assessed by Western blot using rabbit polyclonal
primary (Rockland), actin (A2066; Sigma), and goat anti-rabbit second-
ary (32460; Pierce, Rockford, IL, USA) antibodies.
2.8 Protein carbonyl detection
The extent of protein carbonyl formation in visceral fat was assessed
using the OxyBlot (Chemicon/Millipore) with modification of the man-
ufacturer’s directions. Protein carbonylsweredeterminedby reactionof
2,4-dinitrophenylhydrazine (DNPH), yielding protein-bound
2,4-dinitrophenylhydrazones that were then detected immunologically.
Toavoidoxidationof proteinsduringhandling, themanufacturer recom-
mends adding a high concentration of thiol [either dithiothreitol (50–
100 mM) or 1–2% b-mercaptoethanol (BME)] to the lysis buffer.
However, the presence of adventitious metals (Fe3+ and Cu2+), com-
monly encountered at up to mM levels in typical buffers, can induce
further protein oxidation by rapid one-electron reduction (Fe3+ + re-
ducing agent Fe2+ and/or Cu2+ + reducing agent Cu1+) with
the reducing agent (DTT or BME) and subsequent initiation of Fenton-
based redox chemistry under ambient oxygen tensions. Therefore, a re-
ducing agent was not used during the processing of samples and the
samples were kept on ice to avoid artificial oxidation.
2.9 Quantitative real-time PCR
Total RNA was extracted from flash-frozen lungs using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). RNA was reverse-transcribed
Figure2 OA-NO2 improves glucose tolerance. (A andB) Fastingbloodglucose (A) andplasma insulin (B) levelsweremeasuredat 20weeks. (C)GTTwas
performed with an ip injection of 1.5 g/kg glucose in 0.9% NaCl at Week 18.5. Data represent mean+ SEM; (A and B) One-way ANOVA; (C) two-way
ANOVA; wP, 0.0001 to NC; ^P, 0.0001 to HFD; #P, 0.01 to HFD; wwwP, 0.0001 to NC and HFD + OA-NO2; wwP, 0.01 to NC and
HFD + OA-NO2; %P, 0.05 to NC; no significance between NC and HFD + OA-NO2 at any time point (n ≥ 6 per group).
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Figure 3 OA-NO2 limits HFD-induced inflammation, normalizes adipokine levels, and prevents generation of protein carbonyls. (A) Pro-inflammatory
cytokines (MCP-1 and IL-6), macrophagemarkers (F4/80 and CD68), and adipokines (adiponectin and leptin) were determined by qPCR in abdominal fat.
(B)Circulating leptin and (C ) adiponectin levelsweremeasuredby radioimmunoassay and Luminex singleplex, respectively. Plasma adiponectin levelswere
normalized to fatmass (g) determined byDEXA in Fig. 1B. (D) PlasmaMIP-1a, IL-6, and TNF-aweremeasured by Luminexmultiplex. (E) Relative protein
carbonyls were determined by DNP hydrazone product detection. Data represent mean+ SEM;wP, 0.001 to NC; ^P, 0.001 to HFD; #P, 0.01 to
HFD;&P, 0.05 toHFD;+P, 0.01 toNC; %P, 0.05 toNC;no significancebetweenNCandHFD +OA-NO2at any timepoint unless noted (n ≥ 6per
group).
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using the iScript cDNA synthesis kit (BioRad, Hercules, CA, USA)
as previously described.19 Gene expression was determined by quan-
titative real-time (RT)-PCR (qPCR) using TaqMan gene expression
assays-on-demand (Applied Biosystems, Foster City, CA, USA) and
normalized to 18S ribosomal RNA or actin using the comparative
Ct method.
2.10 Statistical analysis
Results are expressed as mean+ SEM. Statistical analysis was per-
formed with the GraphPad Prism, and the data were analysed by
one-way or two-way analysis of variance (ANOVA) with Tukey’s mul-
tiple comparison post hoc comparisons and Student’s t-test. All results
are considered significant at P, 0.05.
Figure 4 OA-NO2 prevents obesity-induced PAH. (A) Representative tracings of PV loops inNC controls (double dashed), HFD (dashed), andHFD +
OA-NO2 groups for the last 6.5 of 20-week feeding (solid). (B–E) Haemodynamic indices were determined at 20 week in NC controls, HFD, and HFD +
OA-NO2-treatedmice for RVESP (B), PVR (C), RVCI (D), and Tau (E). Data representmean+ SEM;wP, 0.01 toNC; #P, 0.05 toHFD; no significance
between NC and HFD +OA-NO2 (n ≥ 6 per group).
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3. Results
3.1 HFD induces obesity and glucose
intolerance
HFD-fed mice gained significantly more weight than the age-matched
controls on NC (Figure 1A). The significant gain in weight was attributed
to adiposity, with increased fat tissue as determined by DEXA atWeek
18.5 (Figure 1B). Additionally, the abdominal fat pads weighed 2.3-fold
more inHFD vs. NCmice (Figure 1C). The treatment of the electrophilic
OA-NO2 for the last 6.5 weeks did not significantly alter body weight,
AT content (determined by DEXA), and abdominal fat pad weight at
the end of study (Figure 1). In these, and all subsequent biochemical
and physiological measurements, control studies showed that vehicle
or native OA administration displayed no significant effect (HFD
Figure 5 OA-NO2 reduces pulmonary vascular remodelling and inflammation. (A) Representative confocal images of vascular remodelling stainedwith
a-SMA and (B) average SM thickness of pulmonary arterioleswere analysed (a-SMA, red; 4′,6-diamidino-2-phenylindole (DAPI), blue; andXO, green). (C)
Lung inflammatory cytokine expression was determined by qPCR using Taqman assays. Data represent mean+ SEM;wP, 0.001 to NC; #P, 0.01 to
HFD; &P, 0.05 to HFD; no significance between NC and HFD + OA-NO2 (n ≥ 6 per group).
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without treatment, 49.9+ 2.6; HFD with vehicle, 50.9+ 0.9; and HFD
withOA, 49.9+ 1.0; n ≥ 6 per group). Fasting blood glucose and insulin
levels were significantly increased in theHFDmice (Figure 2A and B), and
mice on HFD had impaired glucose tolerance determined by GTT
(Figure 2C).
3.2 OA-NO2 improves glucose tolerance
HFD-induced fasting blood glucose levelswere normalized byOA-NO2
administration, returning to levels similar to NC-fed mice (159.9+2.6,
NC; 203.5+ 4.0, HFD; and 169.6+2.6, HFD +OA-NO2; Figure 2A).
OA-NO2 also significantly reduced blood insulin levels (1.4+0.3,
NC; 7.1+1.2, HFD; and 3.9+ 0.7, HFD + OA-NO2; Figure 2B). The
GTT revealed that HFD mice treated with OA-NO2 disposed of the
glucose load more effectively than the HFD mice, displaying a glucose
tolerance that was similar to NC controls (Figure 2C).
3.3 OA-NO2 limits HFD-induced
inflammatory responses in visceral AT
Pro-inflammatory cytokines and adipokines synthesized and secreted
from visceral ATs have been implicated in the pathogenesis of
obesity-induced insulin resistance and diabetes.1,24 Consistent with
this, MCP-1 and IL-6 mRNA levels were increased in the visceral fat
from HFD compared with NC, whereas OA-NO2 treatment blocked
these HFD-induced inflammatory responses. Additionally, macrophage
markers (F4/80 and CD68) and leptin mRNA levels were significantly
elevated in the visceral AT from the HFD mice, whereas adiponectin
mRNA levels were decreased. OA-NO2 administration increased adi-
ponectin mRNA levels and significantly decreased macrophage infiltra-
tion and adipose leptin expression (Figure 3A). Consistent with this,
blood leptin levels were 20-fold higher in the HFD compared with
NC mice (147.5+12.6 vs. 7.2+0.8 ng/mL, respectively). OA-NO2
Figure 6 OA-NO2-mediated reduction in XO activity rescues HFD-induced PAH. (A) Lung XO activity and (B) representative PV loops for HFD
(dashed) and HFD + febux (solid) (B). (C–F) Febuxostat effects on lung XO activity (C), RVESP (D), RV CI (E), and Tau (F). Data represent
mean+ SEM; (A) one-way ANOVA,wP, 0.001 to NC; ^P, 0.001 to HFD; (C–F ) t-test, #P, 0.05 to HFD (n ≥ 6 per group).
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suppressed HFD-induced leptin levels, reaching the levels observed
prior to initiation of the treatment at Week 13.5 (59.7+9.1 vs.
66.0+ 2.6 ng/mL) (Figure 3B). Conversely, circulating adiponectin
levels were significantly decreased in the HFD mice compared with
NC. OA-NO2 fully normalized the HFD-mediated decrease in plasma
adiponectin levels (Figure3C). In addition toHFD-inducedadipokinedys-
regulation, systemic inflammatory cytokineswere significantly increased
in theplasmaofHFDmice comparedwithNCandwere alsonormalized
by OA-NO2 administration (Figure 3D). This suggests that OA-NO2
improved AT function in HFDmice, thus normalizing pro-inflammatory
cytokine, leptin, and adiponectin levels in the systemic circulation.
3.4 Oxidative stress blunted in
OA-NO2-treated HFDmice
Elevated levels and reactions of oxidative inflammatorymediators play a
pathogenic role in obesity-induced metabolic syndrome. A reliable sur-
rogatemarker for oxidative stress (amino acid and lipid oxidation) is the
detection of the more stable protein carbonyl derivatives via the reac-
tion of DNPH.25 There was an approximately two-fold increase in the
oxidation of protein carbonyls from the visceral fat depot of HFD
mice compared with NC, an increase that was significantly attenuated
by OA-NO2 (Figure 3E). This observation and the measurement of in-
flammatory mediators indicate that OA-NO2 administration blunted
circulating and visceral fat pro-inflammatory cytokine and adipokine
levels and decreased oxidative stress in HFD mice.
3.5 HFD-induced obesity results in PH
The potential development of PH was assessed by the RV PV relation-
ship using a micromanometer-conductance catheter inserted into the
RV via the right internal jugular vein. Representative RV PV loops
show a rightward shift of the end-systolic PV relationship (ESPVR) for
HFD (dashed) compared with NC (double-dashed) mice (Figure 4A).
HFD mice displayed a lower stroke volume and decreased contractility
(ESPVR shifted rightward). RVESP was elevated in HFD compared with
NC mice (37.7+ 3.4 vs. 21.5+ 1.5 mmHg, P, 0.05). HFD mice had
increased PVR (Figure 4C), decreased RV systolic function [RV contract-
ility index (CI)] (Figure 4D), and altered RV diastolic function (Tau,
Figure 4E) compared with NC. Notably, there were no significant
changes in LV end-diastolic pressure (LVEDP), LV CI, LV Tau, and
LVESP of mice on HFD and NC (see Supplementary material online,
Table S1). This indicates that C57Bl/6j mice consuming a HFD for 20
weeks develop physiological manifestations of PH. Additionally, this
will be referred as PH (pre-clinical model), but the low LV pressures
suggest that this is a model of PAH.
3.6 OA-NO2 protects against HFD-induced
PH
OA-NO2 administration shifted RV PV loops back to the left in the
HFD-fed mice (solid line) (Figure 4A). OA-NO2 also significantly
reduced RVESP (24.7+ 1.1 mmHg) in HFD mice (Figure 4B, P, 0.05),
decreased PVR to levels similar to NC-fed mice [0.76+ 0.05
(OA-NO2) vs. 0.72+0.06 (NC), Figure 4C, P, 0.05], limited the reduc-
tion in systolic function [90.3+7.4 (HFD), 121.8+9.4 (HFD +
OA-NO2), and141+ 2.9 (NC), Figure4D], andpreserveddiastolic func-
tion (Tau) [6.7+0.7 (HFD), 4.0+ 0.4 (HFD + OA-NO2), and 4.2+
0.36 (NC), Figure 4E]. Changes in pressure, resistance, systolic function,
and diastolic function were reflected by the HFD-induced decrease in
CO, with OA-NO2 treatment returning CO to levels reflective of NC
mice (see Supplementary material online, Table S1). Additionally,
OA-NO2 treatment abrogated (16.6+ 0.7) HFD-induced elevation of
mean PAP [24.6+ 2.3 (HFD) vs. 14.0+0.3 (NC)]. The ratio of
RVESP-to-stroke volume [effective arterial elastance (Ea), a measure
of afterload4] was increased by HFD [1.5+0.2 (HFD) vs. 0.94+0.05
(NC)] and rescuedbyOA-NO2 (0.87+0.1). Finally,OA-NO2 reversed
HFD-mediated increases in the Fulton Index (Table 1).
3.7OA-NO2 preventsHFD-induced vascular
remodelling and inflammation in the lung
Immunostaining and quantitative image analysis (Figure 5B, P, 0.05) of
pulmonary arterioles for a-SMA (red) show thickened medial walls in
HFD (Figure 5A, middle panel) compared with NC mice (left panel).
This increase in SMA was significantly reduced by OA-NO2 (right
panel). Additionally, macrophage infiltration was increased in HFD
lungs, a response that was significantly blunted by OA-NO2 (F4/80
and CD68 qPCR, Figure 5C). The HFD also significantly induced
steady-state mRNA expression of MIP-1a, IL-6, TNF-a, inducible NO
synthase, and matrix metalloproteinase 9. OA-NO2 treatment sup-
pressed the expression of these inflammatory mediators in HFD mice
to levels observed in NC-fed mice.
3.8 HFD feeding induces XO-dependent
pulmonary vascular dysfunction
HFD feeding resulted in a significant increase of XO activity in the lung
comparedwithNC (213.9+6.2 vs. 101.1+16.2 mU/mgprotein); a re-
sponse thatwas blockedbyOA-NO2 administration (112.3+13.2 mU/
mg protein), Figure 6A. Increases in XO catalytic activity were not paral-
leled by detectable increases inXOprotein expression, although plasma
XO levels were increased three-fold (not shown), suggesting that
endothelial-bound XO may have been removed during fixation/
washing. Representative RV PV loops for HFD mice (dashed) and
HFD mice treated with the XO-specific inhibitor febuxostat for the
last 6.5 weeks (solid) are shown in Figure 6B. Lung XO activity
(Figure 6C), RVESP (Figure 6D), and Tau (Figure 6F) were significantly
reduced by febuxostat compared with HFD controls. Febuxostat also
improved systolic function (Figure 6E).
4. Discussion
The adverse impact of obesity on systemic vascular disease is well
established, with the link between obesity and the development of
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Haemodynamic function in NC, HFD, and HFD
treated with OA-NO2
HFD
NC – OA-NO2
mPAP (mm Hg) 14.0+0.3 24.6+2.3w 16.6+0.7#
RV Ea 0.94+0.05 1.54+0.19w 0.87+0.12#
Fulton Index
(RV/LV + S)
0.226+0.008 0.272+0.005w 0.226+0.009#
Data represent mean+ SEM.
wP, 0.05 to NC; #P, 0.05 to HFD (n ≥ 6 per group).
Nitroalkenes improve obesity-related metabolic dysfunction Page 9 of 12
 at U
niversity of Pittsburgh on February 16, 2014
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
pulmonary vascular diseases less well defined. A pathogenic role for
obesity in PH is supported by post-mortem observation of a greater
prevalence of pulmonary hypertensive changes in blood vessels of
obese subjects.26 The REVEAL registry also reported a higher inci-
dence of idiopathic PAH in overweight and obese subjects,27 reinfor-
cing the correlation between obesity and the development of
pulmonary vascular disease. Herein, a 20-week HFD induced the de-
velopment of obesity, right ventricular pathology indicative of PH,
and allied inflammatory mediator expression in C57Bl/6j male mice,
whereas the administration of electrophilic OA-NO2 improved AT
function and glucose tolerance, inhibited PH, and potently blocked
multiple indices of inflammation.
Electrophilic unsaturated fatty acid nitroalkene derivatives are meta-
bolic and inflammatory by-products that mediate a broad range of anti-
inflammatory and vascular-protective actions due to their regulation of
transcription factor and enzyme function. In particular, NO2-FAs in-
creaseNObioavailability via endothelial NO synthase phosphorylation,
activate nuclear factor, erythroid derived 2, like 2 (Nrf2)-dependent
gene expression, serve as partial agonists of peroxisome proliferator-
activated receptor g, induce heat shock factor-1 regulated gene
expression, and inhibit NFkB-regulated target gene expression. The
pleiotropic modulation of these signalling pathways by electrophilic
lipids limits inflammation and oxidative stress, thereby promoting car-
diovascular protection.16
Multiple sources of reactive species contribute to obesity-induced
vascular pathology, includingXO,NADPHoxidases, and auto-oxidation
of mitochondrial respiratory chain components. In particular, XO activ-
ity is elevated in PH and its oxidant products impair NO signalling and
vascular function.12–14 The inhibition ofXOusing allopurinol onlymod-
estly limits PH in rodent models, possibly due to the limited capacity of
allo/oxypurinol to inhibit endothelial cell-associated XO, a situation
often noted during inflammatory and hypoxic conditions.28 For
example, while clinically achievable plasma allo/oxypurinol levels
(30–90 mM) successfully lower uric acid levels and alleviate gout
symptoms, there is only modest inhibition of oxidant formation by
XO. In addition, concentrations of allo/oxypurinol approximately four-
fold greater than maximal clinical concentrations (400 mM) only mod-
estly reduce XO activity and oxidant when XO is immobilized by endo-
thelial cell glycosaminoglycans (GAGs). Since GAG sequestration is a
key site of vascular XOcompartmentalization in vivo, febuxostat was uti-
lizedbecauseofmorepotent inhibition kinetics for both ‘free’ andGAG-
bound XO when compared with allopurinol (729-fold, Ki ¼ 0.96 vs.
700 nM).29 This pharmacological approach was also favoured over
genetic strategies since (a) XO2/2 and XO+/2 mice die within 30
days after birth, and (b) inflammatory conditions promote XO release
to the circulation where it can impact remote tissues, confounding the
utility of tissue-specific conditional XO knockouts.18,30
The rationale for testing OA-NO2 as a therapeutic for PH included:
(a) superior inhibition kinetics for XO, (b) inhibition properties are
not affected by the association of XO to vascular GAGs,18 (c) a capacity
to reduce inflammatory cell NADPH oxidase-dependent reactive
species generation,31 and (d) an ability to decrease pro-inflammatory
geneexpression16 thereby improving vascular functionandNObioavail-
ability. The actions of OA-NO2 in limiting the pathobiology of
obesity-induced PH are likely even more complex because of the mul-
tiple enzymatic and transcriptional regulatory mechanisms that are
affected. Ongoing studies are directed towards better understanding
these events in humans, in concert with dose-escalating human safety
studies, using DNA and RNA sequencing strategies.
Obesity induces inflammatory responses in AT that originate from
adipocytes and surrounding resident macrophages, resulting in
adipose dysfunction and aberrant adipokine production.6,7 This inflam-
matorymilieu induces systemic inflammation throughmultiple signalling
mediators, including increased levels of leptin, TNF-a, IL-6, vascular cell
adhesion molecule, and C-reactive protein (CRP). HFD-induced adipo-
kine dysregulation (reflected by increased circulating leptin and
decreased adiponectin levels), coupledwith the pro-inflammatory cyto-
kine responses, oxidative stress, and macrophage infiltration in visceral
AT (Figure 3) resulted in glucose intolerance (Figure 2C). Administration
of OA-NO2 to HFD mice blunted the expression of pro-inflammatory
cytokines, macrophage infiltration, and indices of, oxidative inflamma-
tory reactions (protein carbonyls) in visceralAT. In turn, this significantly
reduced circulating pro-inflammatory cytokines and normalized circu-
lating adipokine levels (both leptin and adiponectin), resulting in
improved AT function and glucose tolerance without significantly de-
creasing body weight and adiposity (Figures 1–3). These results
support that OA-NO2 abrogates HFD-induced pro-inflammatory
responses and oxidative stress, effects that may be further affected by
modest but not statistically significant decreases in body weight.
By activating inflammatory mediator expression in AT, obesity also
promotes insulin resistance and chronic systemic inflammation that is
strongly associated with the prevalence of CVD.1 These obesity-
induced inflammatory processes mediate the initiation and progression
of pulmonary vascular remodelling and increased PVR. Plasma levels of
IL-6, TNF-a, and circulating CRP predict outcomes in patients with
PH,9,32 reinforcing the causal linkage between obesity, inflammation,
and the development of PH.
Adipokine dysregulation has been implicated in the pathogenesis of
PH.3 For example, adiponectin knockout mice are more prone to pul-
monaryarterial remodelling;33 theoverexpressionof adiponectin is pro-
tective in murinemodels of PH34 and apoE2/2 malemice on aHFD had
significantly lower circulating adiponectin levels, insulin resistance, and
developed PH.35 Herein, HFD-mediated suppression of circulating adi-
ponectin mRNA expression in visceral fat was blunted by the treatment
of OA-NO2. Plasma leptin levels (and mRNA levels in visceral AT) are
also significantly decreased following the administration of OA-NO2
without significant changes in adiposity (Figure 3). Additionally, leptin
levels are elevated in idiopathic PAH patients and have been linked
with endothelial dysfunction.36 This affirms that adiponectin and leptin
synthesized and secreted by the AT play an important role in the patho-
genesis of PH, and the levels of these circulating adipokines are strongly
modulated by OA-NO2 administration.
Moreover, the expansion of fat mass correlates with systemic oxida-
tive stress, both clinically and in animal models. Obesity elevates the
pathogenic reactions of oxidative inflammatory mediators by increasing
the rates of generation of reactive species [O2
·2, hydroxyl radical (·OH)
and H2O2] while decreasing anti-oxidant enzyme activity (CuZnSOD
and catalase).37 Reactive species induce protein and lipid oxidation to
carbonyl-containing products that can be detected by measuring the
stable dinitrophenyl (DNP) hydrazone product of 2,4-DNPH reac-
tion.25 Therewas a significant increase in the oxidationof protein carbo-
nyls (DNP hyrdrazone adduct) in visceral AT from HFD mice, when
compared with NC mice (Figure 3E). Treating the HFD mice with
OA-NO2 significantly decreased the DNP hydrazone adducts to
levels similar to those found in the age-matched NC mice.
The oxidant-generating enzymes XO and NADPH oxidase are sig-
nificantly elevated in AT.37,38 Furthermore, blocking reactive species
(O2
·2 and H2O2) production using pharmacological inhibitors attenuate
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pro-inflammatory cytokine levels, normalizes adipokine levels, and
improves AT function and insulin sensitivity.37 Additionally, XO inhib-
ition lowereduric acid levels, decreasedpro-inflammatory cytokinepro-
duction in adipocytes, and reduced insulin resistance in an obesemouse
model.38 These studies coupledwith our findings demonstrate that inhi-
biting enzymes capable of generating reactive species can greatly
improve AT function and glucose tolerance.
The links between obesity and insulin resistance are well established.
An accumulation of visceral AT promotes low-grade chronic inflamma-
tion, which results in insulin resistance. Elevated levels of acute phase
proteins (CRP), cytokines (IL-6), chemokines (MCP-1), and adipokines
(leptin) all lead to insulin resistance.7Thesepro-inflammatory responses
have also been implicated in the pathogenesis of PH.8 Moreover, insulin
resistance is an important risk factor for the initiation and progression of
PH, suggesting that treatments designed to improve insulin sensitivity
can benefit patientswith PH.39 These findings support that insulin resist-
ance can also contribute to the development of PH.
The connection with obesity and PH should be fairly evident;
however, the links are not quite as clear clinically and in animal models
possibly due to confounding issues with comorbidities. While obesity
is common in the PH population,39–41 whether obesity itself can
cause PH is less well defined because glucose intolerance and/or
insulin resistance are commonly linked with obesity. Thus, obesity is
linked with both PH and pulmonary venous hypertension (PVH) with
amajority of patients also havingmetabolic syndromeand/or diabetes.42
This precept is reflected in animal models of obesity that display AT
dysfunction, adipokine dysregulation, hyperglycaemia, and insulin
resistance.
The current finding that OA-NO2 has therapeutic potential in the
contextofobesity-inducedPH isnovel, although themechanismsunder-
lying this effect arenot completely clear. In the current study,wepresent
evidence that both adipokine dysregulation and increased oxidative
stress are present in ourmodel and can be corrected byOA-NO2 treat-
ment.However, our studyhas limitationsprecluding thedecisiveconclu-
sion that OA-NO2-mediated protection of adipokine function and
oxidative stress are the sole pathways responsible for this effect. This
studywas limited in the number of experiments using the right ventricle.
Further studies are planned to assess the impact of OA-NO2 treatment
on obesity-mediated alteration of redox balance in the right ventricle in
order to determine whether the observed protective effects from the
haemodynamic measurements (RVESP, PVR, and RV hypertrophy)
couldbe strictly due toadecrease inoxidative stress in the right ventricle
alone. Additional studies are needed to elucidate an exact signalling
pathway such as the inhibition of XOusing conditional XOR knockouts.
These studieswill determine the exact roleofXO inobesity-inducedPH
and impaired glucose tolerance as well as the inhibitory contribution of
OA-NO2.Ourpreviousworkhasdemonstrated thatNO2-FAspotently
activate the Nrf2 pathway.15,16 Altering the levels of Nrf2 by either de-
creasing the levels using conditional knockouts of Nrf2 (or using Keap1
overexpressingmice) or by increasing the levels by overexpressingNrf2
in particular tissues (by using Keap1 hypomorphic mice) will help shed
light on the potential role of Nrf2 in our model.
In summary, mice subjected to a HFD for 20 weeks displayed an
increased pro-inflammatory oxidant and pro-inflammatory cytokine/
adipokine response, developed hyperglycaemia, and elevated insulin
levels. Haemodynamic measurements indicated the development of
PH. There were no significant changes in LVEDP at Week 20, ruling
out concomitant PVH. Following the onset of obesity, OA-NO2 admin-
istration at Week 13.5 inhibited HFD-induced pro-inflammatory
cytokine/adipokine responses and improved glucose tolerance,
reflected by decreased fasting blood glucose and insulin levels which
coincided with protection from HFD-induced PH. These findings,
coupledwith the inhibitionofXO-derived reactive species andoxidative
stress, shed new light on a potential therapeutic strategy for PH. The
pleiotropic actions of electrophilic fatty acid signalling mediators were
essential in broadly limiting the adverse vascular remodelling and dys-
function in this model of obesity and PH.
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